NZ733260A - Methods for isolation of platelets - Google Patents
Methods for isolation of plateletsInfo
- Publication number
- NZ733260A NZ733260A NZ733260A NZ73326015A NZ733260A NZ 733260 A NZ733260 A NZ 733260A NZ 733260 A NZ733260 A NZ 733260A NZ 73326015 A NZ73326015 A NZ 73326015A NZ 733260 A NZ733260 A NZ 733260A
- Authority
- NZ
- New Zealand
- Prior art keywords
- prp
- platelets
- blood
- plasma
- stem cells
- Prior art date
Links
- 210000001772 Blood Platelets Anatomy 0.000 title claims abstract description 162
- 238000002955 isolation Methods 0.000 title claims abstract description 16
- 210000004623 Platelet-Rich Plasma Anatomy 0.000 claims abstract description 178
- 210000004369 Blood Anatomy 0.000 claims abstract description 70
- 239000008280 blood Substances 0.000 claims abstract description 70
- 210000004700 Fetal Blood Anatomy 0.000 claims abstract description 44
- 210000002381 Plasma Anatomy 0.000 claims description 47
- 210000002826 Placenta Anatomy 0.000 claims description 36
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 20
- 238000005119 centrifugation Methods 0.000 claims description 18
- 210000003743 Erythrocytes Anatomy 0.000 claims description 14
- 210000000265 Leukocytes Anatomy 0.000 claims description 9
- CWSZBVAUYPTXTG-UHFFFAOYSA-N 5-[6-[[3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxymethyl]-3,4-dihydroxy-5-[4-hydroxy-3-(2-hydroxyethoxy)-6-(hydroxymethyl)-5-methoxyoxan-2-yl]oxyoxan-2-yl]oxy-6-(hydroxymethyl)-2-methyloxane-3,4-diol Chemical group O1C(CO)C(OC)C(O)C(O)C1OCC1C(OC2C(C(O)C(OC)C(CO)O2)OCCO)C(O)C(O)C(OC2C(OC(C)C(O)C2O)CO)O1 CWSZBVAUYPTXTG-UHFFFAOYSA-N 0.000 claims description 6
- 239000003058 plasma substitute Substances 0.000 claims description 6
- 238000004108 freeze drying Methods 0.000 claims description 4
- 239000008188 pellet Substances 0.000 claims description 4
- 229940027278 Hetastarch Drugs 0.000 claims description 3
- 229920001612 Hydroxyethyl starch Polymers 0.000 claims description 3
- 229920002123 Pentastarch Polymers 0.000 claims description 3
- 229940101738 Pentastarch Drugs 0.000 claims description 3
- 238000007710 freezing Methods 0.000 claims description 2
- 239000006228 supernatant Substances 0.000 claims 2
- 230000003139 buffering Effects 0.000 claims 1
- 230000008929 regeneration Effects 0.000 abstract description 11
- 238000011069 regeneration method Methods 0.000 abstract description 11
- 210000000056 organs Anatomy 0.000 abstract description 8
- 230000029663 wound healing Effects 0.000 abstract description 8
- 230000000735 allogeneic Effects 0.000 abstract description 7
- 230000017423 tissue regeneration Effects 0.000 abstract description 6
- 238000002360 preparation method Methods 0.000 abstract 1
- 210000000130 stem cell Anatomy 0.000 description 156
- 239000000203 mixture Substances 0.000 description 129
- 230000003169 placental Effects 0.000 description 94
- 208000005230 Leg Ulcer Diseases 0.000 description 56
- 210000004027 cells Anatomy 0.000 description 56
- 206010040943 Skin ulcer Diseases 0.000 description 43
- 238000002347 injection Methods 0.000 description 24
- 239000007924 injection Substances 0.000 description 24
- 200000000019 wound Diseases 0.000 description 22
- 239000011159 matrix material Substances 0.000 description 18
- -1 tPA Chemical compound 0.000 description 17
- 239000000017 hydrogel Substances 0.000 description 16
- 210000001519 tissues Anatomy 0.000 description 16
- 210000000988 Bone and Bones Anatomy 0.000 description 15
- 206010061246 Intervertebral disc degeneration Diseases 0.000 description 15
- 229920000371 poly(diallyldimethylammonium chloride) polymer Polymers 0.000 description 15
- 206010068760 Ulcers Diseases 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 231100000397 ulcer Toxicity 0.000 description 14
- 208000004210 Pressure Ulcer Diseases 0.000 description 13
- 238000002560 therapeutic procedure Methods 0.000 description 13
- 102100017063 NT5E Human genes 0.000 description 12
- 101710039712 NT5E Proteins 0.000 description 12
- 208000002193 Pain Diseases 0.000 description 12
- 239000000463 material Substances 0.000 description 12
- 102000004965 antibodies Human genes 0.000 description 11
- 108090001123 antibodies Proteins 0.000 description 11
- 239000003550 marker Substances 0.000 description 11
- 239000000560 biocompatible material Substances 0.000 description 9
- 230000001809 detectable Effects 0.000 description 9
- 102100003404 HLA-G Human genes 0.000 description 8
- 108010024164 HLA-G Antigens Proteins 0.000 description 8
- 101710026246 POU5F1 Proteins 0.000 description 8
- 102100019163 POU5F1 Human genes 0.000 description 8
- 201000002193 degenerative disc disease Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 238000003860 storage Methods 0.000 description 8
- 108060001251 CD34 Proteins 0.000 description 7
- 102100016492 CD34 Human genes 0.000 description 7
- 206010011985 Decubitus ulcer Diseases 0.000 description 7
- 206010012601 Diabetes mellitus Diseases 0.000 description 7
- 210000002683 Foot Anatomy 0.000 description 7
- 210000002414 Leg Anatomy 0.000 description 7
- 210000003491 Skin Anatomy 0.000 description 7
- 239000004599 antimicrobial Substances 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 238000002513 implantation Methods 0.000 description 7
- 210000001691 Amnion Anatomy 0.000 description 6
- 102100003279 CD38 Human genes 0.000 description 6
- 102100020458 HLA-A Human genes 0.000 description 6
- 108010075704 HLA-A Antigens Proteins 0.000 description 6
- 230000001413 cellular Effects 0.000 description 6
- 238000007906 compression Methods 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 230000001737 promoting Effects 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 108090000623 proteins and genes Proteins 0.000 description 6
- 102100013180 KDR Human genes 0.000 description 5
- 108090000028 MMP12 Proteins 0.000 description 5
- 210000004379 Membranes Anatomy 0.000 description 5
- 102000003729 Neprilysin Human genes 0.000 description 5
- 229920001577 copolymer Polymers 0.000 description 5
- 201000009910 diseases by infectious agent Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- 239000006260 foam Substances 0.000 description 5
- 239000002609 media Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 206010003210 Arteriosclerosis Diseases 0.000 description 4
- 101700078950 CD44 Proteins 0.000 description 4
- 102100003735 CD44 Human genes 0.000 description 4
- 102100019451 CD80 Human genes 0.000 description 4
- 101700080477 CD80 Proteins 0.000 description 4
- 102000015789 HLA-DP Antigens Human genes 0.000 description 4
- 108010010378 HLA-DP Antigens Proteins 0.000 description 4
- 102100017157 PROM1 Human genes 0.000 description 4
- 101700033975 PROM1 Proteins 0.000 description 4
- 102100005499 PTPRC Human genes 0.000 description 4
- 101700059076 PTPRC Proteins 0.000 description 4
- 229920000954 Polyglycolide Polymers 0.000 description 4
- 206010040844 Skin exfoliation Diseases 0.000 description 4
- 210000000278 Spinal Cord Anatomy 0.000 description 4
- 210000003371 Toes Anatomy 0.000 description 4
- 210000003462 Veins Anatomy 0.000 description 4
- 230000002378 acidificating Effects 0.000 description 4
- 239000003146 anticoagulant agent Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 229920001436 collagen Polymers 0.000 description 4
- 239000012530 fluid Substances 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 239000007972 injectable composition Substances 0.000 description 4
- 150000002500 ions Chemical class 0.000 description 4
- 230000004807 localization Effects 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 210000000845 Cartilage Anatomy 0.000 description 3
- 102000008186 Collagen Human genes 0.000 description 3
- 108010035532 Collagen Proteins 0.000 description 3
- 206010056340 Diabetic ulcer Diseases 0.000 description 3
- 206010021639 Incontinence Diseases 0.000 description 3
- 102100016985 KIT Human genes 0.000 description 3
- 101710009391 KIT Proteins 0.000 description 3
- 102100008333 THY1 Human genes 0.000 description 3
- 101700026084 THY1 Proteins 0.000 description 3
- 210000003954 Umbilical Cord Anatomy 0.000 description 3
- 102100019577 VCAM1 Human genes 0.000 description 3
- 101700058634 VCAM1 Proteins 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 206010048038 Wound infection Diseases 0.000 description 3
- 210000002517 Zygapophyseal Joint Anatomy 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 230000027455 binding Effects 0.000 description 3
- 239000006172 buffering agent Substances 0.000 description 3
- 229960005188 collagen Drugs 0.000 description 3
- 239000002131 composite material Substances 0.000 description 3
- 230000003412 degenerative Effects 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 210000001699 lower leg Anatomy 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 201000008482 osteoarthritis Diseases 0.000 description 3
- 229920001610 polycaprolactone Polymers 0.000 description 3
- 230000002035 prolonged Effects 0.000 description 3
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000002522 swelling Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 101700039001 ACE Proteins 0.000 description 2
- 208000008035 Back Pain Diseases 0.000 description 2
- 101700044948 CD38 Proteins 0.000 description 2
- 102100002212 CXCR4 Human genes 0.000 description 2
- 101710003734 CXCR4 Proteins 0.000 description 2
- 229920001287 Chondroitin sulfate Polymers 0.000 description 2
- KXKPYJOVDUMHGS-OSRGNVMNSA-N Chondroitin sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](OS(O)(=O)=O)[C@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](C(O)=O)O1 KXKPYJOVDUMHGS-OSRGNVMNSA-N 0.000 description 2
- 102000012422 Collagen Type I Human genes 0.000 description 2
- 108010022452 Collagen Type I Proteins 0.000 description 2
- 102000003972 Fibroblast Growth Factor 7 Human genes 0.000 description 2
- 108090000385 Fibroblast Growth Factor 7 Proteins 0.000 description 2
- 210000000474 Heel Anatomy 0.000 description 2
- 229920002971 Heparan sulfate Polymers 0.000 description 2
- 229960002897 Heparin Drugs 0.000 description 2
- ZFGMDIBRIDKWMY-PASTXAENSA-N Heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 102100004115 ICAM1 Human genes 0.000 description 2
- 101700051176 ICAM1 Proteins 0.000 description 2
- 208000003618 Intervertebral Disc Displacement Diseases 0.000 description 2
- 101700033678 KDR Proteins 0.000 description 2
- 101710030888 KDR Proteins 0.000 description 2
- 102000004058 Leukemia inhibitory factor Human genes 0.000 description 2
- 108090000581 Leukemia inhibitory factor Proteins 0.000 description 2
- 206010050219 Lumbar radiculopathy Diseases 0.000 description 2
- 210000003205 Muscles Anatomy 0.000 description 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 210000002993 Trophoblasts Anatomy 0.000 description 2
- 208000000558 Varicose Ulcer Diseases 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 230000002429 anti-coagulation Effects 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000003115 biocidal Effects 0.000 description 2
- 229960000074 biopharmaceuticals Drugs 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000002458 cell surface marker Substances 0.000 description 2
- 229910010293 ceramic material Inorganic materials 0.000 description 2
- 229940059329 chondroitin sulfate Drugs 0.000 description 2
- 230000001684 chronic Effects 0.000 description 2
- 238000005138 cryopreservation Methods 0.000 description 2
- 230000002338 cryopreservative Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000003527 fibrinolytic agent Substances 0.000 description 2
- 239000012595 freezing medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 201000002113 hereditary lymphedema I Diseases 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000002519 immonomodulatory Effects 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000001506 immunosuppresive Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000006011 modification reaction Methods 0.000 description 2
- 230000036961 partial Effects 0.000 description 2
- 229920000747 poly(lactic acid) polymer Polymers 0.000 description 2
- 229920002627 poly(phosphazenes) Polymers 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000004062 sedimentation Methods 0.000 description 2
- 239000004332 silver Substances 0.000 description 2
- 229910052709 silver Inorganic materials 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 229960000103 thrombolytic agents Drugs 0.000 description 2
- 230000000472 traumatic Effects 0.000 description 2
- WKPUACLQLIIVJJ-RHKLHVFKSA-M (2S,3R,4R,5S,6R)-4-hydroxy-3-methoxy-6-[(2S,3R,4S,5S,6R)-6-methoxy-4-oxido-5-(sulfooxyamino)-2-(sulfooxymethyl)oxan-3-yl]oxy-5-sulfooxyoxane-2-carboxylate Chemical compound [O-][C@H]1[C@H](NOS(O)(=O)=O)[C@H](OC)O[C@@H](COS(O)(=O)=O)[C@@H]1O[C@H]1[C@@H](OS(O)(=O)=O)[C@H](O)[C@@H](OC)[C@@H](C([O-])=O)O1 WKPUACLQLIIVJJ-RHKLHVFKSA-M 0.000 description 1
- BQCIDUSAKPWEOX-UHFFFAOYSA-N 1,1-difluoroethene Chemical compound FC(F)=C BQCIDUSAKPWEOX-UHFFFAOYSA-N 0.000 description 1
- JRHWHSJDIILJAT-UHFFFAOYSA-M 2-hydroxypentanoate Chemical compound CCCC(O)C([O-])=O JRHWHSJDIILJAT-UHFFFAOYSA-M 0.000 description 1
- LCSKNASZPVZHEG-UHFFFAOYSA-N 3,6-dimethyl-1,4-dioxane-2,5-dione;1,4-dioxane-2,5-dione Chemical compound O=C1COC(=O)CO1.CC1OC(=O)C(C)OC1=O LCSKNASZPVZHEG-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- 229960004676 ANTITHROMBOTIC AGENTS Drugs 0.000 description 1
- 102000005416 ATP-Binding Cassette Transporters Human genes 0.000 description 1
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 229940002273 Anbesol Drugs 0.000 description 1
- 210000001367 Arteries Anatomy 0.000 description 1
- 210000002469 Basement Membrane Anatomy 0.000 description 1
- BLFLLBZGZJTVJG-UHFFFAOYSA-N Benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000010392 Bone Fractures Diseases 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N Bupivacaine Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 206010006797 Burns first degree Diseases 0.000 description 1
- 206010006802 Burns second degree Diseases 0.000 description 1
- 206010006803 Burns third degree Diseases 0.000 description 1
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L Calcium sulfate Chemical class [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 1
- 229940107161 Cholesterol Drugs 0.000 description 1
- 210000001612 Chondrocytes Anatomy 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 206010009802 Coagulopathy Diseases 0.000 description 1
- 102000004266 Collagen Type IV Human genes 0.000 description 1
- 108010042086 Collagen Type IV Proteins 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- AVJBPWGFOQAPRH-FWMKGIEWSA-L Dermatan sulfate Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@H](OS([O-])(=O)=O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](C([O-])=O)O1 AVJBPWGFOQAPRH-FWMKGIEWSA-L 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 208000008960 Diabetic Foot Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101710007023 ESAG4 Proteins 0.000 description 1
- 210000004177 Elastic Tissue Anatomy 0.000 description 1
- 210000001671 Embryonic Stem Cells Anatomy 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 210000000981 Epithelium Anatomy 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 210000002744 Extracellular Matrix Anatomy 0.000 description 1
- 102100008658 FN1 Human genes 0.000 description 1
- 210000003195 Fascia Anatomy 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 210000001654 Germ Layers Anatomy 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N HEPES Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 102000006354 HLA-DR Antigens Human genes 0.000 description 1
- 108010058597 HLA-DR Antigens Proteins 0.000 description 1
- 229940088597 Hormone Drugs 0.000 description 1
- 102100001478 ITGB1 Human genes 0.000 description 1
- 101710006661 ITGB1 Proteins 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 206010050296 Intervertebral disc protrusion Diseases 0.000 description 1
- 210000000281 Joint Capsule Anatomy 0.000 description 1
- 208000009883 Joint Disease Diseases 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 210000003127 Knee Anatomy 0.000 description 1
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 description 1
- 208000007450 Leg Injury Diseases 0.000 description 1
- 206010061225 Limb injury Diseases 0.000 description 1
- 208000008930 Low Back Pain Diseases 0.000 description 1
- 210000004705 Lumbosacral Region Anatomy 0.000 description 1
- 206010025135 Lupus erythematosus Diseases 0.000 description 1
- 108020004999 Messenger RNA Proteins 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 210000000944 Nerve Tissue Anatomy 0.000 description 1
- 206010052639 Nerve injury Diseases 0.000 description 1
- 206010029331 Neuropathy peripheral Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000003076 Osteolysis Diseases 0.000 description 1
- 229920002201 Oxidized cellulose Polymers 0.000 description 1
- 206010033775 Paraesthesia Diseases 0.000 description 1
- 206010033892 Paraplegia Diseases 0.000 description 1
- 208000001297 Phlebitis Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 239000004698 Polyethylene (PE) Substances 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001451 Polypropylene glycol Polymers 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N Procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229940097325 Prolactin Drugs 0.000 description 1
- 102000003946 Prolactin Human genes 0.000 description 1
- 108010057464 Prolactin Proteins 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 108060007720 RAD16 Proteins 0.000 description 1
- 229940116157 Regranex Drugs 0.000 description 1
- 108010081750 Reticulin Proteins 0.000 description 1
- 101710038665 SELE Proteins 0.000 description 1
- 102100003520 SELE Human genes 0.000 description 1
- 102100008254 SELL Human genes 0.000 description 1
- 101710038663 SELL Proteins 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 208000007056 Sickle Cell Anemia Diseases 0.000 description 1
- 206010072170 Skin wound Diseases 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M Sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 206010041591 Spinal osteoarthritis Diseases 0.000 description 1
- 208000005801 Spondylosis Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229940076185 Staphylococcus aureus Drugs 0.000 description 1
- 241000191963 Staphylococcus epidermidis Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 210000002435 Tendons Anatomy 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 1
- 229960001727 Tretinoin Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H Tricalcium phosphate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 210000003932 Urinary Bladder Anatomy 0.000 description 1
- 241001459538 Ute Species 0.000 description 1
- 102000008790 VE-cadherin Human genes 0.000 description 1
- 206010047115 Vasculitis Diseases 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Xylocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- ATMLPEJAVWINOF-UHFFFAOYSA-N acrylic acid acrylic acid Chemical compound OC(=O)C=C.OC(=O)C=C ATMLPEJAVWINOF-UHFFFAOYSA-N 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 230000001464 adherent Effects 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000003444 anaesthetic Effects 0.000 description 1
- 230000001455 anti-clotting Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000000845 anti-microbial Effects 0.000 description 1
- 230000000702 anti-platelet Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007172 antigens Proteins 0.000 description 1
- 102000038129 antigens Human genes 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000003190 augmentative Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000002457 bidirectional Effects 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 238000006065 biodegradation reaction Methods 0.000 description 1
- 239000005312 bioglass Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 229920001400 block copolymer Polymers 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 108010018828 cadherin 5 Proteins 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 235000012255 calcium oxide Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000011132 calcium sulphate Nutrition 0.000 description 1
- KMQAPZBMEMMKSS-UHFFFAOYSA-K calcium;magnesium;phosphate Chemical class [Mg+2].[Ca+2].[O-]P([O-])([O-])=O KMQAPZBMEMMKSS-UHFFFAOYSA-K 0.000 description 1
- BRPQOXSCLDDYGP-UHFFFAOYSA-N calcium;oxygen(2-) Chemical class [O-2].[Ca+2] BRPQOXSCLDDYGP-UHFFFAOYSA-N 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000022534 cell killing Effects 0.000 description 1
- 239000002771 cell marker Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 231100000749 chronicity Toxicity 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000001472 cytotoxic Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000001804 debridement Methods 0.000 description 1
- 229940051593 dermatan sulfate Drugs 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000003511 endothelial Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing Effects 0.000 description 1
- 230000003628 erosive Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000000628 gas gangrene Diseases 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 201000010238 heart disease Diseases 0.000 description 1
- 230000002949 hemolytic Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 239000000416 hydrocolloid Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical class CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 238000002684 laminectomy Methods 0.000 description 1
- 230000003902 lesions Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000003589 local anesthetic agent Substances 0.000 description 1
- 238000007898 magnetic cell sorting Methods 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000001404 mediated Effects 0.000 description 1
- 229920002106 messenger RNA Polymers 0.000 description 1
- 200000000023 metastatic cancer Diseases 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 230000000051 modifying Effects 0.000 description 1
- 201000009251 multiple myeloma Diseases 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000001453 nonthrombogenic Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 229920000620 organic polymer Polymers 0.000 description 1
- 230000000399 orthopedic Effects 0.000 description 1
- 229940107304 oxidized cellulose Drugs 0.000 description 1
- 230000001717 pathogenic Effects 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 235000021317 phosphate Nutrition 0.000 description 1
- 229920000406 phosphotungstic acid polymer Polymers 0.000 description 1
- 238000000554 physical therapy Methods 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920001467 poly(styrenesulfonates) Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920003226 polyurethane urea Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 101700032180 psaA Proteins 0.000 description 1
- 230000003016 quadriplegic Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reduced Effects 0.000 description 1
- 239000004627 regenerated cellulose Substances 0.000 description 1
- 230000000268 renotropic Effects 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000000391 smoking Effects 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 125000000542 sulfonic acid group Chemical group 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 238000011099 tissue engineering Methods 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 241001148471 unidentified anaerobic bacterium Species 0.000 description 1
- 201000002282 venous insufficiency Diseases 0.000 description 1
- QYKIQEUNHZKYBP-UHFFFAOYSA-N vinyl ether Chemical compound C=COC=C QYKIQEUNHZKYBP-UHFFFAOYSA-N 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- 239000003357 wound healing promoting agent Substances 0.000 description 1
Abstract
Provided herein are methods for the isolation of platelets, for example, isolation of platelets from umbilical cord blood. In certain embodiments, presented herein are methods for preparation of platelet rich plasma. In one aspect, provided herein are methods for isolation of platelets from blood. In certain embodiments, presented herein are methods for isolation of platelets from cord blood, e.g., human cord blood. The isolated platelets can be used for a variety of applications, including, for example, methods of wound healing, organ repair and/or regeneration, and/or tissue repair and/or regeneration, in either autologous or allogeneic settings. n certain embodiments, presented herein are methods for isolation of platelets from cord blood, e.g., human cord blood. The isolated platelets can be used for a variety of applications, including, for example, methods of wound healing, organ repair and/or regeneration, and/or tissue repair and/or regeneration, in either autologous or allogeneic settings.
Description
/068044
METHODS FOR ISOLATION OF PLATELETS
This application claims benefit of US. Provisional Patent Application No.
62/098,795, filed December 31, 2014, the disclosure of which is incorporated by reference
herein in its entirety.
1. FIELD
Provided herein are methods for isolation of platelets, for example, isolation of
platelets from umbilical cord blood. In n embodiments, the methods presented herein
comprise ation of platelet rich plasma (PRP).
2. OUND
Platelets are normal cellular components of blood. Although very small, platelets are
known to n various types of vesicles that carry a number of factors, e.g., growth factors,
with potentially ial characteristics.
3. SIHVIMARY
In one aspect, provided herein are methods for isolation of platelets from blood. In
certain ments, ted herein are methods for ion of platelets from cord blood,
e. g., human cord blood. The isolated platelets can be used for a variety of applications,
ing, for example, methods of wound healing, organ repair and/or regeneration, and/or
tissue repair and/or regeneration, in either autologous or allogeneic settings.
In particular embodiments, platelets are separated from blood, for example cord
blood, e.g., human cord blood, after erythrocyte removal from the blood. In specific
embodiments, after erythrocyte removal, the resulting plasma is processed to separate the
platelets in the plasma from other plasma components, for example, cellular components such
as leukocytes.
In one embodiment, ocytes are removed from blood via centrigugation. In
another embodiment, erythrocytes are removed from blood by utilizing a medium comprising
components that result in erythrocyte sedimentation, either spontaneously or via
centrifugation. In a particular embodiment, such a medium comprises a plasma volume
expander, for e, hetastarch or pentastarch.
In one embodiment after erythrocyte removal from blood, for example cord blood,
e. g., human cord blood, the resulting plasma is processed to enrich for the presence of
platelets in the plasma, thereby producing platelet rich plasma (PRP). For example, plasma
W0 2016/109655 PCT/U82015/068044
can be depleted for leukocytes, thereby enriching the platelet component of the plasma. In a
specific embodiment, the plasma can be centrifuged, for example, centriguged at 200 to
SOOxG, e.g., 300-400xG, for a time sufficient to separate leukocytes from platelets in the
plasma, for example, for 5, 10, 15, 20, 25, or 30 minutes, e.g., 10-30 minutes, 10-20 minutes,
or 10-15 minutes. In such an embodiment, the resulting leukocyte-depleted plasma is platelet
rich plasma (PRP).
In certain embodiments, prior to use or to storage, the PRP can be processed to yield a
desired platelet concentration. In one embodiment, for example, the PRP can be centrifuged
at 2000xG to 4000xG, e.g., 2000xG, for 10-20 minutes, e.g., for 15 minutes, pelleting and
removing the resulting atant, to yield a desired PRP et concentration. In other
embodiments, for example, the PRP can be centrifugued at SOOXG to 2000xG for 20-60
minutes to yield a d PRP platelet concentration.
In particular embodiments, ets are isolated from blood, for example cord blood,
e.g., human cord blood, after the blood has been processed to te stem cells from the
blood. In other particular ments, platelets can be isolated from blood, for example
cord blood, e.g., human cord blood, without prior stem cell preservation. For e, blood,
for example cord blood, e.g., human cord blood, can be processed to produce PRP by
centrifugation, e.g., via lOO-SOOxG, for e, lOO-200XG, for 10-30 minutes, for
example, 20-25 minutes. The resulting PRP can then be processed to pellet and remove the
platelets from the remaining plasma.
In certain embodiments, the PRP is buffered prior to use. In another embodiment, the
platelets in the PRP are separated from the remainder of the plasma, e.g., via centrifugation,
and resuspended in a buffer prior to use.
In certain embodiments, the PRP is buffered prior to use. In another embodiment, the
platelets in the PRP are separated from the der of the plasma, e.g., via centrifugation,
and resuspended in a buffer prior to use.
In one embodiment, the PRP can be used ately after generation. In certain
embodiments, the PRP is buffered prior to use. In another embodiment, the ets in the
PRP are separated from the remainder of the plasma, e.g., via centrifugation, and resuspended
in a buffer prior to use.
In yet another embodiment, the PRP can be stored for further use. For e, the
PRP can be frozen or otherwise cryopreserved for further use. In other embodiments, the
PRP can be freeze-dried for further use. For e, freeze-dried PRP can be
cryopreserved. In another example, freeze-dried PRP can be stored at room temperature
under vacuum.
In another embodiment, the platelets in the PRP are separated from the remainder of
the plasma, e.g., via centrifugation, and resuspended in a buffer prior to storage. For
e, the platelets in the PRP can ted from the remainder of the , e.g., via
centrifugation, and resuspended in a buffer prior to being frozen or otherwise cryopreserved
for further use. In other embodiments, the platelets in the PRP are separated from the
remainder of the plasma, e.g., via fugation, and resuspended in a buffer prior to being
freeze—dried for further use. Freeze-dried platelets can, for example, be eserved. In
another e, freeze-dried ets can be stored at room temperature under vacuum.
In certain embodiments, the PRP is buffered prior to storage. In another embodiment,
the platelets in the PRP are ted from the remainder of the plasma, e.g., via
centrifugation, and resuspended in a buffer suitable for storgage, e.g., cryopreservation, prior
to e.
In certain s, provided herein is a composition comprising the isolated PRP
formulated to be administered to an individual, for example, administered by injection, e.g,
local injection. In certain other aspects, provided herein is a composition comprising the
isolated platelets formulated to be administered to an individual, for example, administered
by injection, e.g., local injection.
In certain aspects, provided herein is a composition comprising the isolated PRP and
stem cells, for example, tal stem cells (PDACs). In n embodiments, such
compositions are formulated to be administered to an individual, for example, administered
by injection, e.g., local injection. In certain other aspects, provided herein is a composition
comprising the isolated platelets and stem cells, for example, PDACs. In certain
embodiments, such compositions are formulated to be stered to an dual, for
example, administered by injection, e.g, local injection.
In some ments, the PRP and stem cells, e.g., placental stem cells, are
combined to form said composition ex vivo prior to administration to, e.g., injection into, an
individual. In other embodiments, the PRP is administered to, e.g., injected into, an
individual in a first step, and the stem cells, e.g., placental stem cells, are administered to,
e. g., injected into, the individual at or near the site of PRP administration in a second step,
thereby forming the composition in vivo. In yet other embodiments, the stem cells, e.g.,
placental stem cells, are administered to, e.g., injected into, an individual in a first step, and
the PRP is administered to, e.g., injected into, the dual at or near the site of stem cell
administration in a second step, thereby forming the composition in vivo.
In other embodiments, the platelets and stem cells, e.g., placental stem cells, are
combined to form said composition ex vivo prior to administration to, e.g., injection into, an
individual. In other embodiments, the platelets are administered to, e.g., ed into, an
individual in a first step, and the stem cells, e.g., placental stem cells, are administered to,
e. g., injected into, the individual at or near the site of platelet administration in a second step,
thereby forming the ition in vivo. In yet other embodiments, the stem cells, e.g.,
placental stem cells, are administered to, e.g., injected into, an individual in a first step, and
the platelets are administered to, e.g., injected into, the individual at or near the site of stem
cell stration in a second step, thereby forming the composition in vivo.
In a specific embodiment, said PDACs are CD10+, CD34‘, CD105+, CD200+
placental stem cells. In another specific embodiment, said PDACs express CD200 and do not
express HLA-G, or express CD73, CD105, and CD200; or express CD200 and OCT-4, or
s CD73 and CD105 and do not express HLA-G. In yet other ments, said
PDACs express one or more of CD44, CD90, HLA-A,B,C, or ABC-p, and/or do not s
one or more of CD45, CD117, CD133, KDR, CD80, CD86, HLH-DR, SSEA3, SSE4, or
CD38. In certain embodiments, the tal stem cells suppress the activity of an immune
cell, e. g., suppress proliferation of a T cell.
In some embodiments, the volume to volume ratio of PRP to stem cells, e.g., placental
stem cells, in the composition is between about 10:1 and 1:10. In some embodiments, the
volume to volume ratio of PRP to stem cells, e.g., placental stem cells, in the composition is
about 1:1. In some embodiments, the ratio of the number of platelets in the PRP to the
number of stem cells, e.g., placental stem cells, is between about 100:1 and 1:100. In some
embodiments, the ratio of the number of platelets in the PRP to the number of stem cells, e.g.,
placental stem cells,is about 1:1.
In certain aspects, provided herein is a composition comprising a matrix, hydrogel or
scaffold, and the isolated PRP. In certain embodiments, such compositions are formulated to
be administered to an dual. In certain other aspects, provided herein is a composition
comprising a , hydrogel or scaffold, and the isolated platelets. In certain embodiments,
such compositions are formulated to be administered to an individual. In ular
embodiments, such compositions comprise a natural matrix, e.g., a placental biomaterial such
as an amniotic membrane material.
WO 09655
In certain aspects, provided herein is a ition comprising a matrix, hydrogel or
scaffold, the isolated PRP and stem cells, for example, PDACs. In certain embodiments,
such compositions are formulated to be administered to an individual. In certain other
aspects, provided herein is a composition sing a matrix, hydrogel or scaffold, the
isolated platelets and stem cells, for example, PDACs. In certain embodiments, such
compositions are formulated to be administered to an individual. In particular embodiments,
such itions comprise a natural matrix, e.g., a placental biomaterial such as an amniotic
membrane material.
In some embodiments, the PRP of the compositions provided herein is autologous
PRP. In some embodiments, the platelets of the compositions are autologous platelets. In
some embodiments, the PRP of the compositions provided herein is allogeneic PRP. In some
embodiments, the platelets of the compositions are allogeneic platelets.
In some embodiments, the PRP is derived from cord blood, e.g., human cord blood.
In some embodiments, the platelets are derived from cord blood, e.g., human cord blood. In
other embodiments, the PRP is derived from placental perfusate, e.g., human placental
ate. In other embodiments, the platelets are d from placental perfusate, e.g,
human placental perfusate.
In particular aspects, the compositions are provided herein are for use in treating a
disease, disorder or medical condition in an individual. For e, provided herein are
methods of promoting wound healing comprising administering a composition provided
herein to an individual in need of wound healing. In r example, provided herein are
methods of promoting ing tissue or organ repair or regeneration, comprising
administering a composition provided herein to an individual in need of tissue or organ repair
or regeneration. In a particular embodiment, provided herein are methods of bone repair or
regeneration comprising administering a composition provided herein to an individual in
need of bone repair or regeneration.
3.1 DEFINITIONS
As used herein, the term “about,” when ing to a stated c value, indicates a
value within plus or minus 10% of the stated numeric value.
As used herein, the term “amount,” when referring to the placental stem cells
described herein, means a particular number of tal cells.
As used herein, the term “stem cell” defines a cell that retains at least one ute of
a stem cell, e.g, a marker or gene expression profile associated with one or more types of
stem cells; the ability to replicate at least 10-40 times in e; multipotency; e.g; the
ability to differentiate, either in vitro; in vivo or both; into cells of one or more of the three
germ layers; the lack of adult (i.e.; entiated) cell characteristics; or the like.
As used herein; the term “derived” means isolated from or otherwise purified. For
example; tal derived adherent cells are isolated from placenta. The term “derived”
encompasses cells that are cultured from cells isolated directly from a tissue; e.g; the
placenta; and cells cultured or ed from primary isolates.
As used herein; “immunolocalization” means the detection of a compound; e.g.; a
cellular marker, using an immune protein, e. g; an antibody or fragment thereof in, for
example; flow cytometry; fluorescence-activated cell sorting; magnetic cell sorting; in situ
hybridization; immunohistochemistry, or the like.
As used herein; the term “SH2” refers to an antibody that binds an epitope on the
marker CD105. Thus; cells that are referred to as 8H2+ are CD105”
As used herein; the terms “SH3” and SH4” refer to antibodies that bind epitopes
present on the marker CD73. Thus; cells that are referred to as SH3+ and/or 8H4” are CD73”
As used herein, cells; e.g., PDACs are “isolated” if at least 50%, 60%; 70%; 80%;
90%; 95%; or at least 99% of other cells with which the stem cells are lly associated
are removed from the stem cells; e.g; during collection and/or culture of the stem cells.
As used herein; the term “isolated population of cells” means a population of cells
that is substantially separated from other cells of the tissue; e.g., placenta; from which the
population of cells is obtained or derived. In some ments; a population of; e.g; stem
cells is “isolated” if at least 50%, 60%, 70%; 80%; 90%, 95%; or at least 99% of the cells
with which the population of stem cells are naturally associated are removed from the
population of stem cells; e.g., during collection and/or culture of the population of stem cells.
As used herein; the term “placental stem cell” refers to a stem cell or progenitor cell
that is d from; e.g; isolated from; a mammalian placenta; regardless of morphology;
cell e markers; or the number of passages after a y culture; which s to a
tissue culture substrate (e.g.; tissue culture plastic or a fibronectin-coated tissue culture plate).
The term “placenta stem cell” as used herein does not; however, refer to a trophoblast; a
cytotrophoblast; nic germ cell; or embryonic stem cell; as those cells are understood
by persons of skill in the art. The terms “placental stem cell” and “placenta-derived stem
cell” may be used hangeably. Unless otherwise noted herein; the term “placental”
includes the umbilical cord. The placental stem cells disclosed herein are, in certain
WO 09655
embodiments, otent in vitro (that is, the cells differentiate in vitro under differentiating
conditions), multipotent in viva (that is, the cells entiate in vivo), or both.
As used herein, a stem cell is “positive” for a particular marker when that marker is
detectable above background, e.g., by immunolocalization, e.g, by flow cytometry, or by
, etc. For example, a cell or cell population is described as positive for, e.g, CD73 if
CD73 is detectable on the cell, or in the cell population, in an amount detectably greater than
background (in comparison to, e.g, an isotype control) or an experimental negative control
for any given assay. In the context of, e.g., antibody-mediated detection, “positive,” as an
tion a particular cell surface marker is present, means that the marker is detectable
using an antibody, e.g., a fluorescently-labeled antibody, specific for that marker, “positive”
also means that a cell or population of cells displays that marker in a amount that es a
signal, e.g., in a cytometer, ELISA, or the like, that is detectably above background. For
example, a cell is “CD105+” where the cell is ably labeled with an antibody specific to
CD105, and the signal from the antibody is detectably higher than a control (e.g,
background). Conversely, “negative” in the same context means that the cell surface marker
is not detectable using an antibody specific for that marker compared to background. For
example, a cell or population of cells is “CD34‘” where the cell or population of cells is not
detectably labeled with an antibody specific to CD34. Unless otherwise noted herein, cluster
of differentiation (“CD”) s are detected using antibodies. For example, OCT-4 can be
determined to be t, and a cell is OCT-4+, if mRNA for OCT-4 is detectable using RT-
PCR, e.g., for 30 cycles. A cell is also positive for a marker when that marker can be used to
distinguish the cell from at least one other cell type, or can be used to select or isolate the cell
when t or sed by the cell.
As used herein, “immunomodulation” and “immunomodulatory” mean causing, or
having the capacity to cause, a detectable change in an immune response, and the ability to
cause a detectable change in an immune response, either systemically or locally.
As used herein, “immunosuppression” and “immunosuppressive” mean causing, or
having the capacity to cause, a detectable reduction in an immune response, and the ability to
cause a detectable ssion of an immune response, either systemically or locally.
4. DETAILED DESCRIPTION
4.1 METHODS OF OBTAINING PLATELETS AND ET RICH
PLASMA
In one aspect, provided herein are methods for isolation of platelets from blood. In
n embodiments, presented herein are methods for isolation of platelets from cord blood,
e. g., human cord blood, or placenta, e.g., human placenta, for example from placental
perfusate.
The source of the platelets isolated using the methods described herein can be from
any from a human or animal source of whole blood. For example, the PRP and isolated
platelets may be ed from an autologous source, an allogeneic source, a single source, or
a pooled source of platelets and/or plasma, e.g., platelets harvested from corde blood, for
example, human cord blood, or placenta, for example human placenta, e.g., from placental
perfusate. For example, a donor that is to be a source of the blood used in the isolation
methods presented herein can be a donor who has not been previously d with a
thrombolytic agent, such as heparin, tPA, or aspirin. In some embodiments, such a donor has
not received a thrombolytic agent for at least 2 hours, 1 day, 2 weeks, or 1 month prior to
withdrawing the blood.
In one embodiment, whole blood may be collected from a donor using a blood
collection syringe. The amount of blood collected may depend on a number of factors,
including, for example, the amount of platelets desired and the health of the donor. Any
le amount of blood may be collected. For example, about 30 to 60 ml of whole blood
may be drawn. In an exemplary embodiment, about 11 ml of blood may be withdrawn into a
syringe that contains about 5 ml of an anticoagulant, such as acid-citrate—phosphate or ephosphate-dextrose
solution. The e may be attached to an apheresis needle, and primed
with the anticoagulant. Blood may be drawn from the donor using standard aseptic practice.
In some embodiments, a local anesthetic such as anbesol, aine, lidocaine, procaine,
bupivicaine, or any appropriate anesthetic known in the art may be used to anesthetize the
insertion area.
In particular embodiments, the platelets are isolated from cord blood, e.g., human
cord blood. Cord blood can be obtained using standard methods well known in the art.
In particular embodiments, platelets are isolated from placenta, e.g., human ta,
for example from placental perfusate. An exemplary method for isolation of placental
perfusate is described below.
The placenta, for example, human placenta, e.g., human, full-term placenta, should be
placed in a sterile, insulated container at room temperature and delivered to the laboratory
within 4 hours of birth. The placenta is discarded if, on inspection, it has evidence of
physical damage such as fragmentation of the organ or avulsion of umbilical s.
Optionally, prior to such delivery, the placenta and any umbilical cord attached o can be
exsanguinated or partially exsanguinated.
The placenta is maintained at room temperature (23°+/-2° C) or refrigerated (4° C) in
sterile containers for 2 to 20 hours. Periodically, the ta is immersed and washed in
sterile saline at 25°+/-3° C to remove any visible e blood or debris. The umbilical cord
is transected imately 5 cm from its insertion into the placenta and the umbilical vessels
are cannulated with Teflon or polypropylene catheters connected to a sterile fluid path
allowing bidirectional perfusion of the placenta and recovery of the effluent fluid.
The placenta is maintained under conditions which simulate and sustain a
logically compatible environment for the tment of cells. The a is flushed
with IMDM serum-free medium (GibcoBRL, NY) containing 2U/ml n (Elkins-Sinn,
N.J.). Perfusion of the placenta is performed at a rate of 50 mL per minute. During the
course of the procedure, the placenta is gently massaged to aid in the perfusion process and
assist in the ry of cellular material. Effluent fluid is collected from the perfusion
circuit by both gravity drainage and aspiration through the arterial cannula.
The perfusion and collection procedures may be repeated until the number of
recovered nucleated cells falls below lOO/microL. The perfusates are pooled and used to
isolate platelets are described heriein.
In particular embodiments, platelets are separated from blood, for example cord
blood, e.g., human cord blood, or placenta, e.g, human placenta, for example from placental
perfusate, after erythrocyte removal from the blood. In c embodiments, after
ocyte removal, the resulting plasma is processed to te the platelets in the plasma
from other plasma ents, for example, cellular components such as leukocytes.
In one embodiment, erythrocytes are removed from blood via centrigugation. In
another ment, erythrocytes are removed from blood by utilizing a medium comprising
components that result in erythrocyte sedimentation, either spontaneously or via
centrifugation. In a particular embodiment, such a medium comprises a plasma volume
expander, for example, hetastarch or pentastarch.
In one embodiment after erythrocyte removal from blood, for e cord blood,
e. g., human cord blood, or placenta, e.g., human placenta, for example from placental
perfusate,the resulting plasma is processed to enrich for the presence of platelets in the
plasma, thereby producing platelet rich plasma (PRP). For example, plasma can be depleted
for leukocytes, thereby enriching the platelet component of the plasma. In a specific
embodiment, the plasma can be centrifuged, for example, centriguged at 200 to 500xG, e.g.,
300-400xG, for a time sufficient to separate leukocytes from ets in the , for
example, for 5, 10, 15, 20, 25, or 30 minutes, e.g., 10-30 minutes, 10-20 minutes, or 10-15
minutes. In such an embodiment, the resulting leukocyte-depleted plasma is platelet rich
plasma (PRP).
In certain embodiments, prior to use or to storage, the PRP can be processed to yield a
desired platelet tration. In one embodiment, for example, the PRP can be centrifuged
at ZOOOXG to 4000XG, e.g., ZOOOXG, for 10-20 minutes, e.g., for 15 minutes, to yield a
desired PRP platelet concentration. In other embodiments, for e, the PRP can be
fugued at 500xG to ZOOOXG for 20-60 minutes to yield a desired PRP platelet
concentration.
In particular embodiments, platelets are isolated from blood, for example cord blood,
e. g., human cord blood, or placenta, e.g., human placenta, for e from placental
perfusate, after the blood has been sed to separate stem cells from the blood. In other
particular embodiments, platelets can be isolated from blood, for example cord blood, e.g,
human cord blood, or placenta, e.g., human ta, for example from placental perfusate,
Without prior stem cell preservation. For example, blood, for example cord blood, e.g.,
human cord blood, or placenta, e.g., human placenta, for example from placental perfusate,
can be processed to produce PRP by centrifugation, e.g., Via lOO-SOOXG, for example, 100-
200xG, for 10-30 minutes, for example, 20-25 minutes. The resulting PRP can then be
processed to pellet and remove the ets from the remaining plasma.
In n embodiments, the PRP is buffered prior to use. In another ment, the
platelets in the PRP are separated from the remainder of the plasma, e.g, Via centrifugation,
and resuspended in a buffer prior to use.
In certain embodiments, the PRP is buffered prior to use. In another embodiment, the
platelets in the PRP are separated from the remainder of the plasma, e.g, Via fugation,
and resuspended in a buffer prior to use.
In one embodiment, the PRP can be used immediately after generation. In certain
ments, the PRP is buffered prior to use. In another embodiment, the platelets in the
PRP are separated from the remainder of the plasma, e.g., Via centrifugation, and resuspended
in a buffer prior to use.
In certain embodiments, the PRP or ended platelets may be buffered using an
alkaline buffering agent to a physiological pH. The buffering agent may be a biocompatible
buffer such as HEPES, TRIS, monobasic phosphate, sic bicarbonate, or any suitable
combination thereof that may be capable of ing the PRP or ressuspended platelets to
physiological pH between about 6.5 and about 8.0. In certain embodiments, the
physiological pH may be adjusted to about pH 7.3 to about pH 7.5, and more specifically,
about pH 7.4. In certain ments, the buffering agent may be an 8.4% sodium
bicarbonate solution. In a particular embodiment, for each cc of PRP isolated from whole
blood, 005 cc of 8.4% sodium bicarbonate may be added.
In yet another embodiment, the PRP can be stored for further use. For example, the
PRP can be frozen or ise cryopreserved for further use. In a specific embodiment, a
cryopreservative such as DMSO, glycerol, or EPILIFETM Cell Freezing Medium (Cascade
Biologics)) is added prior to ng.
In other embodiments, the PRP can be freeze-dried for further use. For example,
freeze-dried PRP can be cryopreserved. In another example, freeze-dried PRP can be stored
at room temperature under vacuum.
In another embodiment, the ets in the PRP are separated from the remainder of
the plasma, e.g., Via centrifugation, and resuspended in a buffer prior to storage. For
example, the platelets in the PRP can ted from the remainder of the plasma, e.g., Via
centrifugation, and resuspended in a buffer piior to being frozen or otherwise eserved
for further use. In a specific embodiment, a cryopreservative such as DMSO, glycerol, or
EPILIFETM Cell Freezing Medium (Cascade Biologics)) is added prior to freezing.
In other embodiments, the platelets in the PRP are separated from the remainder of
the plasma, e.g., Via centrifugation, and resuspended in a buffer prior to being freeze—dried for
further use. Freeze-dried platelets can, for example, be cryopreserved. In another example,
freeze-dried platelets can be stored at room temperature under vacuum.
In certain embodiments, the PRP is buffered prior to storage. In another embodiment,
the ets in the PRP are separated from the remainder of the plasma, e.g., Via
centrifugation, and resuspended in a buffer le for storgage, e.g., cryopreservation, prior
to storage.
4.2 ITIONS COMPRISING PLATELETS AND PLATELET RICH
PLASMA
In certain aspects, ed herein is a composition comprising the isolated PRP
obtained via the methods presented herein. In some embodiments, compositions ed
herein comprise PRP which comprises platelet cells at a concentration of at least 1.1-fold
greater than the concentration of platelets in whole blood, e.g., unprocessed whole blood,
used to generate the PRP. In some embodiments, a ition provided herein comprises
PRP that comprises platelet cells at a concentration of about 1.1-fold to about 10-fold greater
than the concentration of platelets in whole blood, e.g, unprocessed whole blood, used to
generate the PRP. In some embodiments, a composition provided herein comprises PRP that
ses platelet cells at a concentration of about 1.5, 2.0, 2.5, 3.0, 3.5, 4, 4.5, 5, 5.5, 6, 6.5,
7, 7.5, 8, 8.5, 9, 9.5, 10-fold, or more than 10-fold greater than the concentration of platelets
in whole blood, e.g, unprocessed whole blood, used to generate the PRP.
In certain other aspects, provided herein is a composition comprising platelets
ed via the methods presented herein. In some embodiments, compositions provided
herein comprise comprise platelet cells at a concentration of at least 1.1—fold greater than the
concentration of platelets in whole blood, e.g., unprocessed whole blood, used to generate
isolated platelets. In some ments, a composition provided herein comprises platelet
cells at a concentration of about 11-fold to about 10-fold greater than the concentration of
platelets in whole blood, e.g., unprocessed whole blood, used to generate the isolated
platelets. In some embodiments, a composition provided herein comprises et cells at a
concentration of about 1.5, 2.0, 2.5, 3.0, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10-
fold, or more than 10-fold greater than the tration of platelets in whole blood, e.g.,
unprocessed whole blood, used to generate the isolated platelets.
Generally, a microliter of whole blood comprises between 0 and 500,000
platelets. In some embodiments, the platelet tration in the compositions provided
herein is between about 150,000 and about 2,000,000 platelets per microliter. In some
embodiments, the platelet concentration in the compositions presented herein is about
150,000, 200,000, 300,000, 400,000, 0, 600,000, 700,000, 800,000, 900,000,
1,000,000, 1,100,000, 1,100,000, 1,200,000, 000, 1,400,000, 1,500,000, 000,
1,700,000, 000, 1,900,000, or 2,000,000 platelets per microliter. In some
embodiments, the et concentration in the compositions presented herein is about
2,500,000 to about 5,000,000, or about 5,000,000 to about 7,000,000 platelets per microliter.
In certain aspects, provided herein is a composition comprising the isolated PRP
formulated to be stered to an individual, for example, administered by injection, e.g.,
local ion. In n other aspects, provided herein is a composition comprising the
isolated platelets ated to be administered to an individual, for example, administered
by injection, e.g., local ion.
In certain aspects, provided herein is a ition comprising the isolated PRP and
stem cells, for example, placental stem cells (PDACs). In n ments, such
compositions are formulated to be administered to an individual, for example, administered
by injection, e.g., local injection. In certain other aspects, provided herein is a composition
comprising the ed platelets and stem cells, for example, PDACs. In certain
embodiments, such compositions are formulated to be administered to an individual, for
example, administered by injection, e.g., local injection.
In some embodiments, the PRP and stem cells, e.g., placental stem cells, are
ed to form said composition ex vivo prior to administration to, e.g., injection into, an
individual. In other embodiments, the PRP is administered to, e.g., injected into, an
individual in a first step, and the stem cells, e.g., placental stem cells, are administered to,
e. g., injected into, the individual at or near the site of PRP administration in a second step,
thereby g the composition in vivo. In yet other embodiments, the stem cells, e.g.,
placental stem cells, are administered to, e.g., injected into, an individual in a first step, and
the PRP is administered to, e.g., injected into, the individual at or near the site of stem cell
administration in a second step, thereby forming the composition in vivo.
In other embodiments, the platelets and stem cells, e.g., placental stem cells, are
combined to form said composition ex vivo prior to administration to, e.g., injection into, an
individual. In other embodiments, the platelets are administered to, e.g, ed into, an
individual in a first step, and the stem cells, e.g., placental stem cells, are administered to,
e. g., injected into, the individual at or near the site of platelet administration in a second step,
thereby forming the composition in vivo. In yet other embodiments, the stem cells, e.g.,
placental stem cells, are stered to, e.g., injected into, an individual in a first step, and
the ets are administered to, e.g., injected into, the individual at or near the site of stem
cell administration in a second step, thereby forming the composition in vivo.
Placental stem cells useful in the compositions and methods described herein are
described herein and, e.g., in US. Patent Nos. 7,311,904, 7,311,905, 7,468,276; 8,057,788,
and 8,202,703, the disclosures of which are hereby incorporated by reference in their
entireties.
In a specific embodiment, said PDACs are CD101 CD341 CD1051 CD200+
placental stem cells. In another specific embodiment, the CD10“, CD34", CD105+, CD200+
placental stem cells are additionally CD45‘ or CD90+. In r specific embodiment, such
cells are additionally CD80‘ and/or CD86-.
In certain embodiments, said placental stem cells are CD34‘, CD10+, CD105+ and
CD2001 and one or more of CD3 8—, CD45: CD80: CD86: CD133: HLA-DR,DP,DQ_,
SSEA3‘, SSEA4‘, CD291 CD441 CD731 CD901 CD1051HLA—A,B,C1PDL11ABC—p1
and/or OCT-4+, as detected by flow cytometry. In other embodiments, any of the CD34‘,
CD10+, CD105+ cells described above are additionally one or more of CD29+, CD3 8—,
CD44+, CD54+, SH3+ or SH4+. In another specific embodiment, the cells are additionally
CD44+. In another specific embodiment of any of the isolated CD34‘, CD10+, CD105+
placental stem cells above, the cells are additionally one or more of CD117‘, CD133‘, KDR‘
(VEGFRZ‘), HLA—A,B,C1 HLA-DP,DQ,DR‘, or Programmed Death-l Ligand (PDL1)1 or
any combination f.
In another embodiment, the CD341 CD101 CD105+ cells are onally one or
more of CD131 CD291 CD331 CD381 CD441 CD451 CD541 CD62E‘, CD62L1 CD62P1
SH3+ (CD73+), SH4+ (CD73+), CD801 CD861 CD901 SH2+ (CD105+), CD106/VCAM1
CD1171 CD144/VE—cadherin‘°W, CXCR41 CD2001 CD1331 OCT—41 SSEA3‘,
SSEA4‘, ABC—p1 KDR‘ (VEGFRZ‘), HLA-A,B,C+, HLA-DP,DQ,DR‘, HLA-G‘, or
Programmed Death-l Ligand (PDL1)+, or any combination thereof. In another embodiment,
the CD341 CD101 CD105+ cells are additionally CD131 CD291 CD331 CD381 CD441
CD451 CD54/ICAM1CD62E‘, CD62L‘, CD62P1 SH3+ (CD73+), SH4+ (CD73+), CD801
CD861 CD901 SH2+ (CD105+), VCAM1 CD1171 CD144/VE—cadherin10W,
CD184/CXCR4‘, CD2001 CD135, OCT-41 SSEA3‘, SSEA4‘, ABC—p1 KDR‘ Z‘),
HLA-A,B,C+, HLA-DP,DQ,DR‘, HLA-G‘, and Programmed Death-l Ligand (PDL1)1
In another specific embodiment, any of the placental stem cells described herein are
additionally ABC-pt as detected by flow cytometry, or OCT-4Jr (POU5F1+), as determined
by e-transcriptase polymerase chain on R), wherein ABC-p is a placentaspecific
ABC transporter protein (also known as breast cancer ance protein (BCRP) and
as mitoxantrone resistance protein (MXR)), and OCT-4 is the Octamer—4 protein (POUSFl).
In another specific ment, any of the placental stem cells described herein are
additionally SSEA3‘ or , as determined by flow cytometry, wherein SSEA3 is Stage
Specific Embryonic Antigen 3, and SSEA4 is Stage Specific Embryonic Antigen 4. In
r c ment, any of the placental stem cells described herein are additionally
SSEA3' and SSEA4'.
In another c embodiment, any of the placental stem cells described herein are
onally one or more of MHC—I+ (e.g., HLA—A,B,C+), MHC-II‘ (e.g, HLA-DP,DQ,DR‘)
or HLA-G‘. In another specific embodiment, any of the placental stem cells described herein
are additionally one or more of MHC-I+ (e.g., IEA-A,B,C+), _ (e.g., HLA-
DP,DQ,DR‘) and HLA—G‘.
In yet another specific embodiment, said PDACs express CD200 and do not express
HLA-G; or express CD73, CD105, and CD200; or express CD200 and OCT-4; or express
CD73 and CD105 and do not express HLA-G. In yet other embodiments, said PDACs
express one or more of CD44, CD90, HLA-A,B,C, or ABC-p, and/or do not express one or
more of CD45, CD117, CD133, KDR, CD80, CD86, HLH-DR, SSEA3, SSE4, or CD38. In
certain embodiments, the placental stem cells suppress the activity of an immune cell, e.g,
suppress proliferation of a T cell.
In some embodiments, the volume to volume ratio of PRP to stem cells, e.g., placental
stem cells, in the composition is between about 10:1 and 1:10. In some embodiments, the
volume to volume ratio of PRP to stem cells, e.g., placental stem cells, in the composition is
about 1:1. In some embodiments, the ratio of the number of ets in the PRP to the
number of stem cells, e.g., placental stem cells, is between about 100:1 and 1:100. In some
embodiments, the ratio of the number of platelets in the PRP to the number of stem cells, e.g.,
placental stem cells,is about 1:1.
In some embodiments, the volume to volume ratio of stem cells, e.g., placental stem
cells, to PRP is about 10:1, 9.5:1, 9:1, 8.5:1, 8:1, 7.5:1, 7:1, 6.5:1, 6:1, 5.5.:1, 5:1, 4.5:1, 4:1,
3.5:1, 3:1,2.5:1,2:1,1.5:1,1:1,121.5,1:2,1:2.5,1:3,1:3.5,1:4,1:4.5,1:5,1:5.5,1:6,1:6.5,
1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1.9.5, or 1:10. In some embodiments, the volume to volume ratio
of stem cells, e.g., placental stem cells, to PRP is about 100:1, 95:1, 90:1, 85:1, 80:1, 75:1,
70:1, 65:1, 60:1, 55.:1, 50:1, 45:1, 40:1, 35:1, 30:1, 25:1, 20:1, 15:1, 10:1, 5:1, 1:1, 1:5, 1:10
1:15,1:20,1:25,1:30,1:35,1:40,1:45,1:50,1:55,1:60,1:65,1;70,1:75,1:80,1:85,1:90,
1.95, or 1:100. In particular embodiments, the ratio of the number of stem cells, e.g.,
placental stem cells, to the number of platelets in the PRP is about 100: 1, 95: 1, 90: 1, 85:1,
80:1, 75:1, 70:1, 65:1, 60:1, 55:1, 50:1, 45:1, 40:1, 35:1, 30:1, 25:1, 20:1, 15:1, 10:1, 5:1,
1:1,1:5,1:101:15,1:20,1:25,1:30,1:35,1:40,1:45,1:50,1:55,1:60,1:65,1,70,1:75,1:80,
1:85, 1:90, 1.95, or 1:100.
The compositions comprising stem cells, e.g., placental stem cells, and PRP or
platelets provided herein can comprise a therapeutically-effective amount of stem cells, e.g.,
placental stem cells, or PRP or platelets, or both. The combination itions can
comprise at least 1 x 104, 5 x104, 1x105,5 x105, 1x106,5 x106, 1x107,5 x107, 1x108,5
x 108, 1 x 109, 5 x 109, 1 x 1010, 5 x 1010, or 1 x 1011 stem cells, e.g., placental stem cells,
platelets, e. g., platelets in PRP, or both, or no more than 1 x 104, 5 x 104, 1 x 105, 5 x 105, 1 x
106, 5 x106, 1x107,5 x107,1x108,5 x108,1x109,5 x109,1x1010,5 x 1010, or 1 x 1011
stem cells, e.g., placental stem cells, platelets, e.g., ets in PRP, or both.
In one embodiment, such a composition comprises about 300 n stem cells, e.g.,
placental stem cells. In certain other embodiments, such a composition comprises a range
from 1 n to 10 n stem cells, e.g., placental stem cells, between 10 million and 1
billion stem cells, e.g., placental stem cells, or between 100 million and 500 million stem
cells, e.g., placental stem cells.
In certain aspects, provided herein is a composition comprising a matrix, hydrogel or
ld, and the isolated PRP. In certain embodiments, such itions are formulated to
be administered to an individual. In certain other aspects, provided herein is a composition
comprising a matrix, hydrogel or scaffold, and the isolated ets. In certain embodiments,
such compositions are formulated to be stered to an individual. In particular
embodiments, such compositions comprise a natural matrix, e.g, a tal biomaterial such
as an ic membrane material.
In certain aspects, provided herein is a composition comprising a matrix, el or
scaffold, the isolated PRP and stem cells, for example, PDACs. In certain embodiments,
such compositions are formulated to be administered to an individual. In certain other
aspects, provided herein is a ition comprising a matrix, hydrogel or scaffold, the
isolated platelets and stem cells, for example, PDACs. In certain embodiments, such
compositions are formulated to be administered to an individual.
In particular embodiments, compositions presented herein comprise a natural matrix,
e.g., a placental biomaterial such as an amniotic membrane material. Such an ic
membrane material can be, e.g., amniotic membrane dissected directly from a mammalian
placenta, fixed or heat-treated amniotic membrane, substantially dry (i.e., <20% H20)
amniotic membrane, chorionic membrane, substantially dry chorionic membrane,
substantially dry amniotic and chorionic membrane, and the like. In certain embodiments,
placental biomaterials on which PRP or isolated platelets and, optionally, stem cells, e.g.,
placental stem cells, can be added are described in Hariri, US. ation Publication No.
2004/0048796, which is orated herein in its entirety. Additionally biomaterials on on
which PRP or isolated ets and, optionally, stem cells, e.g., placental stem cells, can be
added are described in Hariri, US. Application Publication No. 2008//0181935, which is
incorporated herein in its entirety.
In other embodiments, compositions presented herein comprise PRP or isolated
platelets and, optionally, stem cells, e.g., placental stem cells, suspended in a hydrogel
on, for example, a hydrogel solution suitable for injection. Suitable hydrogels for such
compositions include, for example, self-assembling peptides, such as RAD16. In one
embodiment, a hydrogel solution comprising PRP or isolated platelets and, optionally, stem
cells, e.g., placental stem cells, can be allowed to harden, for instance in a mold, to form a
matrix for implantation. In embodiments comprising stem cells, e.g., placental stem cells,
such a matrix can also be cultured so that the cells are mitotically expanded prior to
implantation. In particular ments, the hydrogel is, e.g, an organic polymer (natural or
tic) that is cross—linked via covalent, ionic, or hydrogen bonds to create a three-
dimensional open-lattice structure that entraps water molecules to form a gel. el—
g materials can include, for e, polysaccharides such as alginate and salts
thereof, peptides, polyphosphazines, and rylates, which are crosslinked ionically, or
block polymers such as polyethylene oxide-polypropylene glycol block copolymers which
are crosslinked by temperature or pH, respectively. In some embodiments, the hydrogel or
matrix is biodegradable.
In some embodiments, a composition presented herein comprises an in situ
polymerizable gel (see, e.g., US. Patent Application Publication 2002/0022676; Anseth er
al., J. Control e, 78(1-3): 199-209 (2002), and Wang el al., ‘erials, 24(22):3969-
80 .
In some embodiments, the rs are at least lly soluble in aqueous solutions,
such as water, buffered salt solutions, or aqueous alcohol ons, that have charged side
groups, or a monovalent ionic salt thereof. Examples of polymers having acidic side groups
that can be reacted with cations are poly(phosphazenes), poly(acrylic acids), poly(methacrylic
acids), copolymers of acrylic acid and methacrylic acid, poly(vinyl acetate), and sulfonated
polymers, such as sulfonated polystyrene. mers having acidic side groups formed by
reaction of acrylic or methacrylic acid and vinyl ether monomers or polymers can also be
used. Examples of acidic groups are carboxylic acid groups, sulfonic acid groups,
halogenated (preferably fluorinated) alcohol groups, phenolic OH groups, and acidic OH
groups.
In n embodiments, compositions presented herein comprise PRP or isolated
platelets and, optionally, stem cells, e.g., placental stem cells, on a three-dimensional
framework or scaffold, e.g., a three-dimensional framework or scafford suitable for
implantation in vivo.
Examples of scaffolds that can be used in such compositions include, for example,
nonwoven mats, porous foams, or self assembling es. Nonwoven mats can be formed,
for example, using fibers comprised of a synthetic absorbable copolymer of glycolic and
lactic acids (e.g, PGA/PLA) (VICRYL, Ethicon, Inc., Somerville, NJ). Foams, composed
of, e.g., poly(3—caprolactone)/poly(glycolic acid) (PCL/PGA) copolymer, formed by
ses such as freeze-drying, or lyophilization (see, e.g., US. Pat. No. 6,355,699), can
also be used as scaffolds. Other scaffolds may, for example, comprise oxidized cellulose or
oxidized regenerated cellulose.
In another embodiment, the scaffold is, or comprises, a brous scaffold, e.g, an
electrospun nanof1brous scaffold. In a more specific embodiment, said nanoflbrous scaffold
comprises poly(L-lactic acid) (PLLA), type I collagen, a copolymer of Vinylidene fluoride
and trifluoroethylnee (PVDF-TrFE), poly(-caprolactone), poly(L-lactide—co-s—caprolactone)
[P(LLA-CL)] (e.g., 75:25), and/or a copolymer of poly(3 -hydroxybutyrate-co
hydroxyvalerate) (PHBV) and type I collagen. In another more specific embodiment, said
scaffold promotes the differentiation of placental stem cells into chondrocytes. Methods of
producing nanoflbrous lds, e.g, ospun nanoflbrous scaffolds, are known in the
art. See, e.g, Xu el al., Tissue Engineering 10(7): 1 160-1 168 (2004), Xu el al., Biomaterials
:877-886 (20040; Meng et al., J. Biomaterials Sci, Polymer Edition 81-94 (2007).
In yet r embodiment, compositions presented herein comprise PRP or isolated
platelets and, optionally, stem cells, e.g., placental stem cells, and a physiologically-
acceptable ceramic material including, for e, mono-, di-, tri-, alpha-tri-, beta-tri-, and
calcium phosphate, hydroxyapatite, fluoroapatites, calcium sulfates, calcium es,
calcium oxides, calcium carbonates, magnesium calcium phosphates, biologically active
glasses such as BIOGLASS®, and mixtures thereof. Porous biocompatible ceramic materials
currently commercially available include, for example, SURGIBONE® dica Corp,
), ENDOBON® (Merck Biomaterial France, France), CEROS® (Mathys, AG,
Bettlach, Switzerland), and mineralized collagen bone grafting products such as HEALOSTM
(DePuy, Inc., m, MA) and VITOSS®, RHAKOSSTM, and CORTOSS® vita,
Malvern, Pa.) The framework can be a mixture, blend or composite of l and/or
synthetic materials.
In another embodiment, compositions presented herein comprise PRP or isolated
platelets and, ally, stem cells, e.g., placental stem cells, and a felt, which can be, e.g,
composed of a multifilament yarn made from a bioabsorbable material such as PGA, PLA,
PCL copolymers or blends, or onic acid.
In a particular embodiment, compositions presented herein comprise PRP or isolated
platelets and, ally, stem cells, e.g., tal stem cells, and a foam scaffold, e.g., a
foam scaffold made of composite structures. Such foam scaffolds can, for example, be
molded into a useful shape, such as that of a portion of a specific structure in the body to be
repaired, replaced or augmented. In some embodiments, the framework is treated, e.g, with
0.1M acetic acid followed by tion in polylysine, PB S, and/or collagen, prior to
inclusion of the PRP or isolated platelets and, optionally, stem cells, e.g., placental stem cells,
to enhance cell attachment. External surfaces of a matrix may, for example, be modified to
improve the attachment or growth of cells and, if desired, differentiation of tissue, such as by
plasma-coating the matrix, or addition of one or more proteins (e.g., collagens, elastic fibers,
reticular fibers), glycoproteins, aminoglycans (e.g, heparin sulfate, chondroitin
sulfate, chondroitinsulfate, dermatan sulfate, keratin sulfate, etc), a cellular matrix, and/or
other als such as, but not limited to, gelatin, alginates, agar, agarose, and plant gums,
and the like.
In some embodiments, the scaffold comprises, or is treated with, materials that render
it non—thrombogenic. These treatments and materials may also e and sustain
endothelial growth, migration, and extracellular matrix deposition. Examples of these
materials and treatments include but are not limited to natural materials such as basement
membrane proteins such as laminin and Type IV collagen, synthetic materials such as
EPTFE, and segmented polyurethaneurea silicones, such as PURSPANTM (The r
Technology Group, Inc., ey, Calif). The scaffold can also comprise anti-thrombotic
agents such as heparin; the scaffolds can also be treated to alter the e charge (e.g.,
g with plasma) prior to g with placental stem cells.
In some embodiments, the PRP of the compositions provided herein is autologous
PRP. In some ments, the platelets of the compositions are autologous platelets. In
some embodiments, the PRP of the compositions provided herein is neic PRP. In some
embodiments, the platelets of the compositions are allogeneic platelets. Provided herein are
compositions comprising placental stem cells ed with platelet rich plasma, wherein
administration of the itions to an individual in need thereof results in prolonged
localization of the placental stem cells at the site of injection or implantation, relative to
administration of placental stem cells not combined with platelet rich plasma. In certain
embodiments, the placental stem cells are human. In other embodiments, the platelet rich
plasma is human, e.g, is obtained from or derived from a human source. In other
embodiments, both the placental stem cells and PRP are human.
In various embodiments, the volume to volume ratio of placental stem cells to et
rich plasma can be between about 10:1 and 1:10.
In other embodiments, transplantation of said composition comprising placental stem
cells combined with platelet rich plasma prolongs localization of the placental stem cells at
the site ofinjection or implantation at least, or at, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14,
, 16, 17, 18, 19, 20 or 21 days post-transplant, relative to lantation of placental stem
cells not combined with platelet rich plasma. In another more specific embodiment, said
composition comprising placental stem cells combined with platelet rich plasma prolongs
localization of the placental stem cells at the site of injection or implantation at least, or more
than 21 days post-transplant. In specific embodiments, said composition comprising
placental stem cells combined with platelet rich plasma prolongs localization of the placental
stem cells at the site of injection or implantation at least, or more than 25, 30, 35, 40, 45, 50,
55 weeks, or 1 year or longer post-transplant.
4.3 PHARMACEUTICAL COMPOSITIONS
Also provided herein are pharmaceutical compositions that comprise PRP or isolated
platelets obtained as described herein, and a pharmaceutically-acceptable r. Further
presented herein are pharmaceutical compositions of the itions presented herein that
comprise PRP or isolated platelets and, optionally, stem cells, e.g., placental stem
cells,combination compositions described , and a pharmaceutically-acceptable carrier.
In one one ent, for example, the PRP or isolated platelets obtained as
bed herein may be formulated as an injectable (see, e.g., WO 96/39101, incorporated
herein by reference in its entirety) comprising a ceutically acceptable carrier. In one
one embodment, for example, the compositions presented herein comprising PRP or isolated
ets obtained as described herein may be formulated as an injectable (see, e.g., WO
01, incorporated herein by reference in its entirety) comprising a ceutically
able carrier. In another embodiment, the compositions presented herein may be
ated using polymerizable or cross linking hydrogels as described, e.g., in US. Patent
Nos. 854; 5,516,532, 5,654,381, and a pharmaceutically acceptable carrier.
In one embodiment, each component of the itions presented herein, e.g., PRP
or isolagted platelets and stem cells, e.g., placental stem cells, may be maintained prior to
use, e.g., prior to stration to an individual, as te pharmaceutical compositions to
be administered tially or jointly to create a composition as described herein in viva.
Each component may be stored and/or used in a separate container, e.g., one bag (e.g., blood
storage bag from Baxter, Becton-Dickinson, Medcep, National Hospital Products, Terumo,
etc.) or separate syringe, which contains a single type of cell or cell population. In a specific
embodiment, PRP or isolated platelets are contained in one bag, and stem cells, e.g.,
placentlal stem cells, for example tal perfusate, or placental stem cells from placental
perfusate, are contained in a second bag.
In a specific embodiment, the pharmaceutical compositions may comprise one or
more agents that induce cell differentiation. In n ments, an agent that induces
differentiation includes, but is not limited to, Ca2+, EGF, Ot-FGF, B-FGF, PDGF, keratinocyte
growth factor (KGF), TGF-B, cytokines (e.g., IL-lOt, IL-lB, IFN-y, TFN), retinoic acid,
transferrin, hormones (e.g., en, estrogen, insulin, prolactin, triiodothyroxine,
ortisone, dexamethasone), sodium butyrate, TPA, DMSO, NMF, DMF, matrix
elements (e.g., en, laminin, heparan sulfate, MATRIGELTM), or combinations f.
In another embodiment, the pharmaceutical composition may comprise one or more
agents that suppress cellular differentiation. In certain embodiments, an agent that suppresses
differentiation includes, but is not limited to, human Delta-l and human Serrate—l
polypeptides (see, Sakano el al., US. Patent No. 6,337,387), leukemia inhibitory factor (LIF),
stem cell factor, or combinations thereof.
The pharmaceutical itions provided herein may, for example, be treated prior
to stration to an individual with a compound that modulates the activity of TNF-u.
Such compounds are sed in detail in, e.g, US. Application Publication No.
2003/0235909, which disclosure is incorporated herein in its entirety.
4.4 METHODS OF UTILIZING PLATELETS AND PLATELET RICH
PLASMA
In particular aspects, the PRP, isolated platelets and compositions provided herein are
useful in treating a disease, disorder or medical condition in an individual. For example,
provided herein are methods of promoting wound healing sing administering PRP,
isolated platelets or a composition provided herein to an individual in need of wound healing.
In another e, provided herein are methods of promoting promoting tissue or organ
repair or regeneration, comprising administering a composition ed herein to an
individual in need of tissue or organ repair or regeneration. In a particular embodiment,
ed herein are methods of bone repair or regeneration comprising administering PRP,
isolated platelets or a composition provided herein to an dual in need of bone repair or
regeneration.
In one embodiment, presented herein are methods of promoting wound healing
comprising administering PRP, isolated platelets or a composition provided herein to an
individual in need of wound g. Such methods comprise treatment of a wound,
including but not limited to: an epidermal wound, skin wound, chronic wound, acute wound,
external wound, internal wound, and a congenital wound (e.g., dystrophic molysis
bullosa). Thus, in another , provided herein is a method of treating an individual
having a wound, comprising administering to the individual a therapeutically-effective
amount of PRP, isolated platelets or a composition as presented herein.
In other embodiments, PRP, isolated platelets or a composition provided herein is
administered to an individual for the treatment of a wound infection, e.g., a wound infection
followed by a breakdown of a surgical or traumatic wound. Such a wound infection can be
from any microorganism known in the art, e.g., microorganisms that infect wounds
originating from within the human body, which is a known reservoir for pathogenic
organisms, or from environmental origin. A non-limiting example of the microorganisms,
the growth of which in wounds may be reduced or prevented by the methods and
compositions described herein are Staphylococcus aureus, S. epidermidis, beta haemolytic
streptococci, Escherichia coli, Klebsiella and Pseudomonas species, and among the anaerobic
bacteria, the Closlridl'um i or C. m, which are the cause of gas gangrene, mainly
in deep traumatic wounds.
In other embodiments, PRP, isolated platelets or a composition ed herein is
administered for the treatment of burns, including but not limited to, first-degree burns,
second-degree burns (partial thickness burns), third degree burns (full thickness burns),
infection of burn wounds, infection of excised and unexcised burn wounds, infection of
grafted wound, infection of donor site, loss of epithelium from a previously grafted or healed
burn wound or skin graft donor site, and burn wound impetigo.
In particular embodiments, PRP, ed platelets or a composition provided herein
can be used in the treatment of ulcers, e.g., leg . In various embodiments, said leg ulcer
can be, for example, a venous leg ulcer, arterial leg ulcer, diabetic leg ulcer, decubitus ulcer,
or split thickness skin grafted ulcer or wound. In this context, “treatment of a leg ulcer”
comprises contacting the leg ulcer with an amount of PRP, isolated platelets or a composition
provided herein effective to improve at least one aspect of the leg ulcer. As used herein,
“aspect of the leg ulcer” includes ively measurable parameters such as ulcer size, depth
or area, degree of inflammation, ingrowth of epithelial and/or mesodermal tissue, gene
sion within the ulcerated tissue that is correlated with the healing s, quality and
extent of scarring etc, and subjectively measurable parameters, such as t well-being,
perception of improvement, perception of lessening of pain or discomfort ated with the
ulcer, patient perception that treatment is successful, and the like.
In particular ments, provided herein are methods for the treatment of venous
leg ulcers comprising administering PRP, isolated platelets or a composition provided herein
effective to improve at least one aspect of the venous leg ulcer. Venous leg ulcers, also
known as venous stasis ulcers or venous insufficiency ulcers, a type of chronic or non-healing
wound, are widely ent in the United States, with approximately 7 million people,
usually the elderly, afflicted. Worldwide, it is estimated that l-l.3% of individuals suffer
from venous leg ulcers. Approximately 70% of all leg ulcers are venous ulcers. Venous leg
ulcers are often located in the distal third of the leg known as the gaiter region, and typically
on the inside of the leg. The ulcer is usually painless unless infected. Venous leg ulcers
typically occur because the valves connecting the superficial and deep veins fail to function
properly. Failure of these valves causes blood to flow from the deep veins back out to the
icial veins. This opriate flow, together with the effects of gravity, causes
swelling and progression to damage of lower leg tissues.
ts with venous leg ulcers often have a history of deep vein thrombosis, leg
injury, obesity, phlebitis, prior vein surgery, and lifestyles that require prolonged standing.
Other factors may contribute to the chronicity of venous leg ulcers, including poor
circulation, often caused by arteriosclerosis, disorders of clotting and ation that may or
may not be related to atherosclerosis; diabetes; renal (kidney) failure; hypertension (treated or
untreated), dema up of fluid that causes swelling in the legs or feet);
atory diseases such as vasculitis, lupus, scleroderma or other rheumatological
conditions, medical conditions such as high cholesterol, heart disease, high blood pressure,
sickle cell anemia, or bowel disorders; a history of smoking (either t or past), pressure
caused by lying in one position for too long, genetics (predisposition for venous disease);
malignancy (tumor or cancerous mass); infections, and certain medications.
Thus, in another embodiment, provided herein is a method of treating a venous leg
ulcer comprising contacting the venous leg ulcer with an amount of PRP, isolated platelets or
a composition provided herein sufficient to improve at least one aspect of the venous leg
ulcer. In another specific embodiment, the method additionally comprises treating an
underlying cause of the venous leg ulcer.
The methods for treating a venous leg ulcer provided herein further encompass
treating the venous leg ulcer by administering a therapeutically effective amount of PRP,
ed platelets or a composition provided herein, in conjunction with one or more therapies
or treatments used in the course of ng a venous leg ulcer. The one or more additional
ies may be used prior to, concurrent with, or after administration of the PRP, isolated
platelets or a composition provided herein. In some embodiments, the one or more additional
therapies comprise compression of the leg to minimize edema or swelling. In some
embodiments, ssion treatments include wearing therapeutic compression stockings,
multilayer compression wraps, or wrapping an ACE bandage or dressing from the toes or foot
to the area below the knee.
Arterial leg ulcers are caused by an insufficiency in one or more arteries’ ability to
deliver blood to the lower leg, most often due to atherosclerosis. Arterial ulcers are usually
found on the feet, ularly the heels or toes, and the borders of the ulcer appear as though
they have been ‘punched out’. Arterial ulcers are frequently painful. This pain is ed
when the legs are lowered with feet on the floor as gravity causes more blood to flow into the
legs. Arterial ulcers are usually associated with cold white or bluish, shiny feet.
The treatment of al leg ulcers contrasts to the treatment of venous leg ulcers in
that compression is contraindicated, as compression tends to bate an already-poor
blood supply, and debridement is limited, if indicated at all. Thus, in another embodiment,
provided herein is a method of treating an arterial leg ulcer comprising treating the
underlying cause of the arterial leg ulcer, e.g, arteriosclerosis, and contacting the arterial leg
ulcer with an amount of PRP, isolated platelets or a composition provided herein sufficient to
improve at least one aspect of the arterial leg ulcer. In a c embodiment, the method of
treating does not comprise ssion therapy.
Diabetic foot ulcers are ulcers that occur as a result of complications from es.
Diabetic ulcers are typically caused by the combination of small arterial blockage and nerve
damage, and are most common on the foot, though they may occur in other areas affected by
neuropathy and pressure. ic ulcers have characteristics similar to arterial ulcers but
tend to be located over pressure points such as heels, balls of the feet, tips of toes, between
toes or anywhere bony prominences rub t bed sheets, socks or shoes.
ent of diabetic leg ulcers is generally similar to the treatment of venous leg
ulcers, though lly without compression; additionally, the underlying es is treated
or managed. Thus, in another embodiment, provided herein is a method of treating a diabetic
leg ulcer comprising treating the underlying es, and ting the diabetic leg ulcer
with an amount of PRP, isolated platelets or a composition provided herein sufficient to
e at least one aspect of the diabetic leg ulcer.
Decubitus ulcers, commonly called bedsores or pressure ulcers, can range from a very
mild pink coloration of the skin, which disappears in a few hours after pressure is relieved on
the area to a very deep wound ing into the bone. Decubitus ulcers occur frequently
with patients subject to prolonged bedrest, e.g., quadriplegics and paraplegics who suffer skin
loss due to the effects of localized pressure. The resulting pressure sores exhibit dermal
erosion and loss of the epidermis and skin appendages. Factors known to be associated with
the development of decubitus ulcers include advanced age, immobility, poor ion, and
incontinence, Stage 1 decubitus ulcers exhibit nonblanchable erythema of intact skin. Stage
2 decubitus ulcers exhibit superficial or partial thickness skin loss. Stage 3 decubitus ulcers
exhibit full thickness skin loss with aneous damage. The ulcer extends down to
underlying fascia, and presents as a deep crater. Finally, stage 4 decubitus ulcers t full
thickness skin loss with extensive destruction, tissue necrosis, and damage to the underlying
muscle, bone, tendon or joint capsule. Thus, in another embodiment, provided herein is a
method of treating a decubitus leg ulcer comprising treating the underlying diabetes, and
contacting the decubitus leg ulcer with an amount of PRP, isolated platelets or a ition
provided herein ent to improve at least one aspect of the decubitus leg ulcer.
Also provided herein are methods of treating a leg ulcer by administering a
composition comprising tal stem cells and platelet rich plasma in conjunction with one
or more therapies or treatments used in the course of treating a leg ulcer. The one or more
additional therapies may be used prior to, concurrent with, or after administration of PRP,
isolated platelets or a composition provided herein. PRP, isolated ets or a ition
provided herein, and one or more additional therapies, may be used where the PRP, isolated
platelets or a composition provided , alone, or the one or more additional therapies,
alone, would be insufficient to measurably improve, maintain, or lessen the worsening of, one
or more aspects of a leg ulcer.
In specific embodiments, the one or more additional therapies comprise, without
tion, treatment of the leg ulcer with a wound healing agent (e.g., PDGF,
REGRANEX®), administration of an anti-inflammatory compound, administration of a pain
medication; administration of an antibiotic; stration of an anti-platelet or anti-clotting
medication; application of a prosthetic; ation of a dressing (e.g., moist to moist
dressings; hydrogels/hydrocolloids; alginate dressings; collagen—based wound dressings;
antimicrobial dressings; composite ngs; synthetic skin substitutes, etc), and the like. In
another embodiment, the onal therapy comprises contacting the leg ulcer with honey.
For any of the above embodiments, in a specific embodiment, the leg ulcer is a venous leg
ulcer, a decubitus ulcer, a diabetic ulcer, or an al leg ulcer.
In another specific embodiment, the additional therapy is a pain medication. Thus,
also provided herein is a method of ng a leg ulcer comprising contacting the leg ulcer
with PRP, isolated platelets or a composition provided herein, and administering a pain
medication to lessen or eliminate leg ulcer pain. In a specific embodiment, the pain
medication is a topical pain medication.
In another specific embodiment, the additional therapy is an anti-infective agent. In
one embodiment, the anti-infective agent is one that is not cytotoxic to healthy tissues
surrounding and underlying the leg ulcer; thus, compounds such as iodine and bleach are
disfavored. Thus, treatment of the leg ulcer, in one embodiment, comprises contacting the
leg ulcer with PRP, isolated platelets or a composition provided herein, and administering an
anti-infective agent. The anti-infective agent may be administered by any route, e.g,
topically, , buccally, intravenously, intramuscularly, anally, etc. In a specific example,
the anti—infective agent is an antibiotic, a bacteriostatic agent, antiviral compound, a virustatic
agent, ngal compound, a fungistatic agent, or an antimicrobial compound. In r
c embodiment, the anti-infective agent is ionic silver. In a more specific embodiment,
the ionic silver is contained within a hydrogel. In specific embodiments, the leg ulcer is a
venous leg ulcer, arterial leg ulcer, decubitus ulcer, or diabetic ulcer.
In another specific embodiment of the methods of treatment described herein, PRP,
isolated platelets or a composition provided herein is used for the treatment of orthopedic
s, including but not limited to, bone defects, disc herniation and rative disc
disease. Thus, in another aspect, provided herein is a method of treating an individual having
a bone defect, disc herniation, or degenerative disc e, comprising administering to the
individual a therapeutically-effective amount of PRP, isolated platelets or a composition
provided herein.
In a ular aspect, provided herein is a method for treating a bone defect in a
t, comprising administering to a subject in need thereof a therapeutically effective
amount of an implantable or injectable ition as described herein sufficient to treat the
bone defect in the subject. In certain embodiments, the bone defect is an osteolytic lesion
associated with a , a bone fracture, or a spine, e.g., in need of fusion. In certain
embodiments, the ytic lesion is associated with multiple myeloma, bone , or
metastatic cancer. In certain embodiments, an implantable composition is administered to the
subject. In certain embodiments, an implantable composition is surgically implanted, e.g., at
the site of the bone . In certain embodiments, an injectable composition is stered
to the subject. In certain embodiments, an injectable composition is surgically administered
to the region of the bone defect.
In particular, presented herein are methods for treatment of herniated discs and
degenerative disc disease comprising administration of PRP, ed platelets or a
composition provided herein. In some embodiments, the degenerative disc disease is
characterized on X-ray tests or MRI scanning of the spine as a narrowing of the normal "disc
space" between the adjacent vertebrae.
Disc degeneration, medically referred to as spondylosis, can occur with age when the
water and protein t of the cartilage of the body changes. This change s in weaker,
more fragile and thin cartilage. Because both the discs and the joints that stack the vertebrae
(facet joints) are partly composed of age, these areas are subject to degenerative
changes, which renders the disc tissue susceptible to herniation. The gradual oration of
the disc between the vertebrae is referred to as degenerative disc disease. Degeneration of the
disc can cause local pain in the affected area, for example, lopathy, i.e., nerve tion
caused by damage to the disc between the vertebrae. In particular, weakness of the outer ring
leads to disc bulging and herniation. As a result, the central softer portion of the disc can
rupture h the outer ring of the disc and abut the spinal cord or its nerves as they exit the
bony spinal column.
Any level of the spine can be affected by disc degeneration. Thus, in some
embodiments, the degenerative disc disease treatable by the methods provided herein is
cervical disc disease, i.e., disc degeneration that affects the spine of the neck, often
accompanied by painful burning or tingling sensations in the arms. In some embodiments,
the degenerative disc disease is thoracic disc disease, i.e., disc degeneration that affects the
mid-back. In some embodiments, the degenerative disc disease is lumbago, 1'.e., disc
degeneration that affects the lumbar spine.
In particular embodiments, the method for treating degenerative disc disease in a
subject ses stering to a subject in need f a therapeutically effective
amount of an implantable or injectable composition described herein sufficient to treat
al or lumbar radiculopathy in the subject. In some embodiments, the lumbar
radiculopathy is anied by incontinence of the bladder and/or bowels. In some
embodiments, the method for treating degenerative disc disease in a subject comprises
administering to a subject in need f a therapeutically effective amount of an
implantable or injectable composition described herein ient to relieve sciatic pain in the
subject.
In some embodiments of the methods of treating disc degeneration in an individual
with PRP; ed platelets or a composition provided herein, wherein the disc degeneration
of the individual occurs at the intervertebral disc between C1 and C2; between C2 and C3;
between C3 and C4; n C4 and C5; between C5 and C6; between C6 and C7; n
C7 and T1; between T1 and T2; between T2 and T3; between T3 and T4; between T4 and T5;
between T5 and T6; between T6 and T7; between T7 and T8; n T8 and T9; between
T9 and T10; between T10 and T11; between T11 and T12; n T12 and L1; between L1
and L2; between L2 and L3; between L3 and L4; or between L4 and L5.
In some embodiments of the methods of treating disc herniation in an individual with
PRP, isolated platelets or a composition provided herein; wherein the disc herniation occurs
at the intervertebral disc between Cl and C2; between C2 and C3; Between C3 and C4;
between C4 and C5; between C5 and C6; between C6 and C7; between C7 and T1; between
T1 and T2; between T2 and T3; between T3 and T4; between T4 and T5; between T5 and T6;
between T6 and T7; between T7 and T8; between T8 and T9; between T9 and T10; between
T10 and T11; between T11 and T12; between T12 and L1; between L1 and L2; between L2
and L3; between L3 and L4; or between L4 and L5.
Degenerative arthritis (osteoarthritis) of the facet joints is also a cause of localized
lumbar pain that can be detected with plain X-ray testing. Wear of the facet cartilage and the
bony changes of the adjacent joint is referred to as degenerative facet joint disease or
osteoarthritis of the spine.
The methods for treating degerative disc disease provided herein further encompass
treating degerative disc disease by stering a eutically effective amount of PRP;
isolated platelets or a composition ed herein; in conjunction with one or more therapies
or treatments used in the course of treating degerative disc disease. The one or more
additional therapies may be used prior to; concurrent with; or after administration of PRP;
isolated ets or a composition provided herein. In some ments; the one or more
additional ies comprise stration of medications to relieve pain and muscles
spasm; cortisone injection around the spinal cord (epidural injection); physical therapy (heat;
massage, ultrasound, electrical stimulation), and rest (not strict bed rest, but avoiding re-
injury),
In some embodiments, the one or more additional ies comprise operative
ention, for example, where the subject presents with unrelenting pain, severe
impairment of function, or incontinence (which can te spinal cord irritation). In some
embodiments, the operative intervention comprises removal of the herniated disc with
laminotomy (producing a small hole in the bone of the spine surrounding the spinal cord),
laminectomy (removal of the bony wall adjacent to the nerve tissues), by needle technique
through the skin (percutaneous discectomy), disc—dissolving procedures (chemonucleolysis),
and .
Equivalents:
The compositions and methods sed herein are not to be limited in scope by the
specific embodiments described herein. Indeed, various modifications of the compositions
and methods in addition to those described will become apparent to those skilled in the art
from the ing description and accompanying figures. Such modifications are intended
to fall within the scope of the appended claims.
Various publications, patents and patent applications are cited herein, the disclosures
of which are orated by reference in their entireties.
Claims (37)
1. A method for isolation of platelets from blood, comprising: removing erythrocytes from the blood to produce plasma, and separating ytes from the .
2. The method of claim 1, wherein the erythrocytes are removed by centrifugation of the blood.
3. The method of claim 2, wherein the erythrocytes are removed by introducing a plasma volume expander into the blood.
4. The method of claim 3, wherein ocytes are spontaneously nted following introduction of the plasma volume expander into the blood.
5. The method of claim 3, wherein erythrocytes are sedimented by centrifugation following introduction of the plasma volume expander into the blood.
6. The method of any one of claims 3 to 5, wherein the plasma volume expander is hetastarch or pentastarch.
7. The method of any one of claims 1 to 6, wherein the plasma is centrifuged for a time sufficient to separate leukocytes from ets in the plasma, thereby ing platelet rich plasma (PRP).
8. The method of claim 7, wherein the plasma is fuged at about 200xG to about SOOxG.
9. The method of claim 7 or 8, wherein the plasma is centrifuged at about 300xG to about 400xG.
10. The method of any one of claims 7 to 9, wherein the plasma is centrifuged for about 5 to about 30 minutes.
11. The method of 10, wherein the plasma is centrifuged for about 10 to about 30 minutes.
12. The method of l 1, wherein the plasma is centrifuged for about 10 to about 20 minutes.
13. The method of 12, wherein the plasma is centrifuged for about 10 to about 15 minutes.
14. A method for isolation of platelets from blood, comprising: centrifuging the blood at about lOOxG to about SOOxG for about 10 minutes to about 30 minutes, thereby producing PRP.
15. The method of claim 14, comprising centrifuging the blood at about lOOxG to about 200xG.
16. The method of claim 14 or 15, comprising centrifuging the blood for about 20 to about 25 minutes.
17. The method of any one of claims 7 tol6, further comprising buffering the PRP.
18. The method of any one of claims 7 to 17, further comprising cryopreserving the PRP.
19. The method of claim 18, wherein crypreserving the PRP comprises ng the PRP.
20‘ The method of claim 18, wherein crypreserving the PRP comprises freeze drying the PRP.
21. The method of 20, r comprising storing the freeze dried PRP at room temperature under vacuum.
22. The method of any one of claims 7 to 16, further comprising: centrifuging the PRP at about 500XG to about 4OOOXG for about 20 to about 60 s to pellet the platelets, and removing the resulting supernatant.
23. The method of claim 22, comprising centrifuging the PRP at about 2000XG to about 4OOOXG for about 10 to about 20 minutes, to pellet the ets, and ng the resulting supernatant.
24. The method of 23, comprising centrifuging the PRP at about 2000XG for about 15 minutes.
25. The method of any one of claims 22 to 24, further comprising resuspending the platelets in a buffer.
26. The method of any one of claims 22 to 25, further comprising cryopreserving the platelets.
27. The method of claim 26, wherein crypreserving the platelets comprises freezing the platelets.
28. The method of claim 26, wherein crypreserving the platelets comprises freeze drying the platelets.
29. The method of 28, further comprising storing the freeze dried platelets at room ature under vacuum.
30. The method of any one of claims 1 to 6, wherein the blood is cord blood.
31. The method of claim 30, wherein the cord blood is human cord blood.
32‘ The method of any one of claims 1 to 6, wherein the blood is from placenta.
33. The method of claim 32, wherein the blood is from human placenta.
34. The method of any one of claims 14 to 16, wherein the blood is cord blood.
35. The method of claim 34, wherein the cord blood is human cord blood.
36. The method of any one of claims 14 to 16, wherein the blood is from placenta.
37. The method of claim 36, n the blood is from human placenta.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62/098,795 | 2014-12-31 |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ733260A true NZ733260A (en) |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021250864A1 (en) | Methods for isolation of platelets | |
KR102136314B1 (en) | Process, tube and device for the preparation of wound healant composition | |
US11000553B2 (en) | Placental tissue composition for for treating cardiac tissue damage | |
US20140106447A1 (en) | Compositions and methods for recruiting stem cells | |
US20170224874A1 (en) | Hydrogels for treating and ameliorating wounds and methods for making and using them | |
WO2016105984A2 (en) | Tissue-based compositions and methods of use thereof | |
JP2021105041A (en) | Use of regenerative cells in mitigating burn progression and improving skin graft incorporation and healing | |
KR20120092632A (en) | Material for induction of hard tissue regeneration | |
Lopresti et al. | Host response to naturally derived biomaterials | |
RU2721116C2 (en) | Compositions for treating tissue injuries | |
Ohlow et al. | Pocket related complications in 163 patients receiving anticoagulation or dual antiplatelet therapy: D-Stat Hemostat™ versus standard of care | |
JP2002504412A (en) | Live chimera skin replacement | |
US20130224148A1 (en) | Activated leukocyte conditioned supernatant and uses for wound healing | |
JP4642765B2 (en) | Insoluble globin injectable implants | |
NZ733260A (en) | Methods for isolation of platelets | |
KR20150061806A (en) | Veterinary composition for wound healing of animal containing activated platelet rich plasma | |
JPH11246420A (en) | Wound curing accelerator | |
US20150283183A1 (en) | Methods for treating cardiac conditions | |
Han | Cell Therapy | |
US11497791B1 (en) | Isolated placental stem cell recruiting factors | |
Guide | Dedicated to.... My | |
Ratan | Study of Efficacy of Autologous Platelet Rich Fibrin Versus Platelet Rich Plasma as a Regenerative Medicine Strategy For Chronic Cutaneous Ulcers. |